December 24, 2012 |
Question: I had an EKG done in 2009 that said I had possible left atrial enlargement. Another EKG done at a different hospital in the same month said I had left atrial abnormality. I saw a cardiologist who did an echocardiogram of my heart and said I did not have left atrial enlargement. I'm completely puzzled! Can you help? Answer: An EKG uses the electrical activity of the heart to look for such things as the heart's rate, rhythm, signs of impaired electrical conduction, prior heart attacks, current injury to heart muscle, and possible enlargement of one or more chambers.
June 26, 2006 |
Dick Jones, 78, of Gladwyne, a prominent graphic designer who volunteered his talents to his community, died June 11 from a head injury at Rhode Island Hospital in Providence. He had fallen June 4 while attending the annual meeting of the Rhode Island School of Design Alumni Council. Mr. Jones retired in 1992 after a 40-year-career but continued to design, his wife, Christine Guarino Jones said. He edited and was creative director of The First 300: The Amazing and Rich History of Lower Merion, published in 2000; designed promotional material for Philadelphia Hospitality; designed newsletters and graphics for ElderNet of Lower Merion/Narberth; and designed material for the Lower Merion Historical Society and Gladwyne Free Library.
December 19, 2000 |
After months of delays, British drugmakers Glaxo Wellcome P.L.C. and SmithKline Beecham P.L.C. said yesterday that the U.S. Federal Trade Commission had approved their $74 billion merger. The FTC said it would continue to review the effects of the merger on the market for products that help people quit smoking, but it did not require the companies to divest products in that market. The companies now face one last government hurdle, a review tomorrow by Britain's High Court.
October 10, 2000 |
SmithKline Beecham P.L.C., which is in the midst of merging with Glaxo Wellcome P.L.C., agreed yesterday to pay $1.24 billion for Block Drug Co., the Jersey City-based maker of Sensodyne toothpaste and Polident denture cleanser. The purchase "will significantly enhance SB's consumer health-care business, which is a key part of our strategy for corporate growth," SmithKline's chief executive officer, Jean-Pierre Garnier, said in a prepared statement. SmithKline's consumer brands include Aquafresh toothpaste, Tums antacid, and Nicorette and Nicoderm antismoking aids.
June 20, 1995 |
A weaker, non-prescription form of the popular anti-ulcer drug Tagamet will be on supermarket shelves soon following its approval yesterday by the U.S. Food and Drug Administration for over-the-counter sale. Its approval as a treatment for occasional heartburn had been widely expected since an FDA advisory committee in March recommended Tagamet be made available without a prescription at lower doses. Tagamet's manufacturer, SmithKline Beecham PLC, plans to announce the FDA approval today of Tagamet HB. Tagamet HB follows Pepcid AC Acid Controller as the second stomach-acid- reduction drug to win FDA over-the-counter approval.
July 29, 1994 |
SmithKline Beecham will have to wait a while longer to get its popular prescription ulcer drug, Tagamet, on the market as an over-the-counter remedy for heartburn. Two Food and Drug Administration advisory committees yesterday recommended against immediate approval of the application, saying they were concerned that Tagamet might cause adverse reactions in people taking certain other medicines. Cited in particular were theophylline, used to treat asthma, and the insomnia drug Halcion.
July 29, 1994 |
SmithKline Beecham was dealt a second setback yesterday in its regulatory quest to turn its prescription ulcer drug Tagamet into an over-the-counter treatment for heartburn. Two panels of advisers to the Food and Drug Administration recommended against approving the drug for OTC sale, saying they were concerned it might react with other drugs patients might be taking. In September, the panels also recommended against over-the-counter-sales, saying tests did not show it to be effective for episodic heartburn.
May 20, 1994 |
Ulcers started flaring up as an item of medical interest this February, when the National Institutes of Health announced that these fires in the belly were caused by bacteria, not stress. It turns out that you can cure them with antibiotics. The news was a belch heard round the world in the field of gastroenterology. More than 4 million Americans whose stomach pain was being managed long-term with drugs stood to have their digestive tracts fixed for good in two weeks flat. Then, last Tuesday, ulcers became a burning issue in international business, when U.S. patent protection expired for Tagamet, sending the pharmaceuticals industry into a frenzy.
May 14, 1994 |
SmithKline Beecham announced yesterday that it had settled a patent and trademark-infringement lawsuit filed against two companies over Tagamet, SmithKline's peptic ulcer medicine. SmithKline filed the lawsuit earlier this week in federal court in Philadelphia, naming as defendants Novopharm USA, a pharmaceuticals manufacturer, and Schein Pharmaceutical Inc., which has agreed to distribute Novopharm's generic cimetidine tablets. Cimetidine is the active component of Tagamet. "We are pleased with this outcome, and we will continue to protect our rights when necessary," said Jerry Karabelas, president of SmithKline Beecham Pharmaceuticals-North America.
April 25, 1994 |
Five years ago, Henry Wendt looked tired, even haggard, as he emerged from months of merger talks that won a suitor for SmithKline Beckman Corp., of Philadelphia. Then he faced a skeptical financial community and a nervous workforce that didn't know what to make of the transatlantic deal with Beecham Group, of Britain. And they wouldn't know for quite some time. Now, as Wendt clears out his spacious corner office and prepares to sever his SmithKline Beecham ties, the company chairman is confident that he made good on his promise to create a firm that would compete "effectively and efficiently, not only in the United States but in the changing European market and expanding economies of Japan and the Pacific Basin.